Top Markets
Coin of the day
Viking Therapeutics, Inc. Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX
Classifica tra le azioni #4213
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
Prezzo delle azioni
$34.45
Capitalizzazione di mercato
$4.02B
Variazione (1 giorno)
0.83%
Variazione (1 anno)
32.31%
Paese
US
Scambia Viking Therapeutics, Inc. (VKTX)

Categoria

Cronologia dei frazionamenti azionari per Viking Therapeutics, Inc. (VKTX)
L’azione Viking Therapeutics, Inc. (simbolo: VKTX) ha subito un totale di 0 frazionamenti.
L’ultimo frazionamento è avvenuto il Aug 26, 2026.
Una quota di VKTX acquistata prima di Aug 26, 2026 equivale oggi a 0 quote di VKTX.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
Non abbastanza dati per le date fornite.
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH